How biotechnology changes pharma R&D: A managerial perspective

International Journal of Biotechnology

Volumn 5, Issue 2, 2003, Pages 125-140

  Chiesa, Vittorio ^a   Toletti, Giovanni ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b POLITECNICO DI MILANO   (Italy)

Author keywords

Bioinformatics; Biotechnology; Genomics; Pharma R D; Proteomics; R D cost drivers; R D led revenue drivers

Indexed keywords

COSTS; DRUG PRODUCTS PLANTS; MARKETING; RESEARCH AND DEVELOPMENT MANAGEMENT;

GENOMICS;

BIOTECHNOLOGY;

BIOTECHNOLOGY; PHARMACEUTICAL INDUSTRY; RESEARCH AND DEVELOPMENT; TECHNOLOGICAL DEVELOPMENT;

BIOINFORMATICS; BIOTECHNOLOGY; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; GENOMICS; PHARMACEUTICS; PROTEOMICS; REVIEW; TECHNOLOGY;

EID: 0142228821     PISSN: 09636048     EISSN: None     Source Type: Journal    
DOI: 10.1504/IJBT.2003.003606     Document Type: Review

References (19)

1. This paper is due to the joint work of the authors; however, Giovanni Toletti wrote Sections 1,3,5 and 6, and Vittorio Chiesa wrote Sections 2 and 4.
2. (2001) 'Integration', Ernst and Young's Eighth Annual European Life Sciences Report 2000, Ernst and Young.
3. Chiesa, V. (1996) 'Separating research from development: evidence from the pharmaceutical industry', European Management Journal, Vol. 14, No. 6, pp.638-647.
4. (2000) 'Convergence', The Biotechnology Industry Report, Ernst and Young.
5. Bhandari, M., Garg, R., Glassman, R., Ma, P.C. and Zemmel, R.W. (1999) 'A genetic revolution in healthcare', McKinsey Quarterly, No. 4, pp.58-67.
6. Edmunds III, R.C., Ma, P.C. and Tanio, C.P. (2001) 'Splicing a cost squeeze into the genomics revolution', McKinsey Quarterly, No. 2, pp.15-18.
7. (2000) 'Evolution' Ernst and Young's Seventh Annual European Life Sciences Report 2000, Ernst and Young.
8. Housman, D. and Ledley, F.D. (1998) 'Why pharmacogenomics? Why now?' Nature Biotechnology, June, Vol. 16, pp.492-493.
9. Kleyn, P.W. and Vesell, E.S. (1998) 'Genetic variation as a guide to drug development', Science, September, Vol. 281, pp. 1820-1821.
10. Persidis, A. (1998) 'The business of pharmacogenomics?' Nature Biotechnology, June, Vol. 16, pp.209-210.
11. Biotech (2000) Life Sciences Changes and Challenges, Burril and Company, San Francisco
12. Biotech (2001) Life Sciences Genomics, Proteomics ... and More, Burril and Company, San Francisco.
13. Yamamura, A. (2000) Impact of Genomics on Cancer Diagnosis, Therapeutics, and Pharmacogenomics, Cambridge Healthtech Institute.
14. Branca, M.A. and Sannes, L.J. (1999) Proteomics: A Key Enabling Tool for Genomics?, Cambridge Healthtech Institute.
15. Frederickson, R.M. (2001) Introduction to Proteomics, Bio.com.
16. High-Throughput Screening is a methodology utilised to quickly screen large numbers of compounds for use as pharmaceuticals or agrochemicals; combinatorial chemistry refers to a set of technologies that are utilised to generate a large number of samples of (new) chemicals which are tested for potential use; drug design is the design of novel drugs based on the structure of proteins that play key roles in human diseases.
17. Frederickson, R.M. (2001) Bioinformatics: an introduction, Bio.com.
18. Agarwal, S., Desai, S., Holcomb, M.M. and Oberoi, A. (2001) 'Unlocking the value in big pharma', McKinsey Quarterly, No. 2, pp.65-73).
19. (1999) 'Optimizing lead selection in silico biology', Advancetech Monitor, Woburn, USA.